Shop by goal

  • Fat Loss
  • Growth Hormone
  • Muscle Growth
  • Tissue Repair
  • Recovery
  • Anti-Aging
  • Cognitive
  • Accessories
  • All compounds →
  • Popular compounds

  • BPC-157
  • TB-500
  • GHK-Cu
  • Retatrutide
  • Tirzepatide
  • Semaglutide
  • All bestsellers →
  • Research resources

  • Certificates of Analysis
  • Compare Compounds
  • Peptide Guides
  • Delivery Guide
  • Track Order
  • Recently viewed

  • All peptide guides
  • Crypto Blog
  • How to Reconstitute
  • Reconstitution Calculator
  • How to Store
  • Protocols
  • Certificates of Analysis
  • Sign In
  • Create Account
  • My Account
  • My Orders
  • My Referrals
  • Log Out
  • Track Order
  • Refer a Friend
  • Follow us on Twitter/X
  • How-to guides

    Premium research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical with a Certificate of Analysis on every lot. Shipped lab-direct, discreet and cold-chain, worldwide. For laboratory research use only.

    Shop

  • All Peptides
  • Fat-Loss Peptides
  • Skin & Anti-Aging
  • Stacks & Protocols
  • Compare Vials
  • Peptide 101
  • Learn

  • Research Blog
  • How-To Guides
  • Certificates of Analysis
  • Community Forum
  • Company

  • About Us
  • Contact
  • FAQ
  • Affiliate Program
  • VIP Club
  • Support

  • Shipping & Delivery
  • Pay with Crypto
  • Live Crypto Prices
  • Refund Policy
  • Privacy
  • Terms
  • Ways to Pay

  • Google Pay
  • Apple Pay
  • Venmo
  • PayPal
  • Crypto
  • Cash App
  • Credit Card
  • SEPA
  • Shop by Compound

  • BPC-157
  • TB-500
  • GHK-Cu
  • Tesamorelin
  • Retatrutide
  • Semaglutide
  • Tirzepatide
  • CJC-1295 (without DAC)
  • View all compounds →
  • Shop by Goal

  • Fat Loss
  • Growth Hormone
  • Muscle Growth
  • Tissue Repair
  • Recovery
  • Anti-Aging
  • Cognitive
  • Accessories
  • Ships worldwide

  • United Kingdom
  • Australia
  • Canada
  • Canada (FR)
  • Ireland
  • Malta
  • Germany
  • France
  • Spain
  • Italy
  • Netherlands
  • Portugal
  • Greece
  • Austria
  • Poland
  • Sweden
  • Finland
  • Denmark
  • Norway
  • Croatia
  • Slovakia
  • Slovenia
  • Estonia
  • Latvia
  • Lithuania
  • Czechia
  • Hungary
  • Romania
  • Bulgaria
  • Belgium
  • Belgium (FR)
  • Luxembourg
  • USA
  • Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.

    All rights reserved. Copyright of New-U held with Hilxera Distribution Services LLC 2026.

    Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.

    © 2026 New-U Research Compounds · new-u.io · @new.u.io

    Tesamorelin

    Pick your pack · how long it lasts

    At 14 mg/wk — select pack size

    1 × 10-vial pack required for packing — samples add on to any pack

    Lab-direct quality — full packs or single-vial samples

    Every batch ships straight from the lab that synthesises it — sealed, tamper-evident, and HPLC-verified to >99% purity with a batch-linked Certificate of Analysis. Buying direct means you pay the lab-direct rate on every vial, with nothing stacked on top.

    Order a full sealed 10-vial research pack for a complete study supply, or add a single-vial sample alongside your pack to trial a new compound first. Same lab, same batch, same verified purity — scaled to whatever your research needs.

    What It's Researched For

    In plain terms, tesamorelin is the most clinically studied compound in this family, best known for research on deep belly fat. Here is what that looks like across the research.

    Belly fat & metabolism

    In clinical human trials, studied for reducing deep visceral abdominal fat over several months while sparing fat just under the skin.

    Liver fat

    Human research investigates whether it lowers fat stored in the liver, a fast-growing area of metabolic study.

    Muscle & lean mass

    Clinical research explores support for lean body mass through the natural rise in growth hormone and IGF-1.

    Cholesterol & triglycerides

    Studied alongside the fat-loss work for improvements in blood-fat markers such as triglycerides.

    Healthy ageing

    Investigated for the age-related GH decline, drawing on the strongest human dataset of any compound in this class.

    Overview

    Tesamorelin is an FDA-approved synthetic GHRH(1-44) analog engineered for DPP-IV resistance, studied for visceral fat reduction, IGF-1 elevation, and metabolic research.

    Tesamorelin is a 44-amino-acid synthetic version of growth hormone releasing hormone (GHRH), the hypothalamic signal that tells the pituitary to pulse out growth hormone. Researchers attached a small trans-3-hexenoic acid tag to the N-terminus, which blocks the DPP-IV enzyme that would otherwise chew up native GHRH within minutes.

    The practical effect is that tesamorelin can survive long enough after a subcutaneous injection to actually drive a physiologic GH pulse. Unlike injecting GH itself, tesamorelin preserves the natural negative-feedback loop - somatostatin can still turn off the pituitary - so you get a more physiological release pattern without overshoot.

    FDA-approved in 2010 for HIV-associated lipodystrophy, tesamorelin is widely studied as a visceral fat reduction tool and is under investigation for metabolic dysfunction-associated steatotic liver disease (MASLD). Supplied here as sterile lyophilised powder for research use.

    Mechanism of Action

    Tesamorelin binds the GHRH receptor on pituitary somatotrophs to drive a natural pulse of growth hormone, which then raises IGF-1 and mobilises visceral fat.

    Pathway Effect Why it matters GHRH receptor Agonist at the pituitary somatotroph GHRHR Triggers calcium-dependent GH exocytosis following a near-native release pattern DPP-IV resistance N-terminal hexenoic acid blocks DPP-IV cleavage Keeps the peptide active long enough to generate a measurable GH pulse Somatostatin feedback Preserves the natural off-switch for GH release Maintains pulsatility and avoids the excess seen with direct GH dosing Hepatic IGF-1 Elevates IGF-1 by 1.5-3× over baseline Drives most of the downstream anabolic and metabolic effects Visceral lipolysis Selectively reduces visceral adipose tissue 18% VAT reduction at 26 weeks in HIV lipodystrophy trials Deeper dive for scientific readers

    Falutz et al. (NEJM, 2007) reported the landmark phase 3 data showing ~18% visceral fat reduction at 26 weeks with 2 mg daily tesamorelin in 412 participants. Stanley et al. (Lancet HIV, 2019) then demonstrated reduced liver fat and slowed fibrosis progression in HIV-associated NAFLD over 12 months, suggesting a role in metabolic dysfunction research beyond lipodystrophy. Elimination half-life is short (~8-26 min) but the GH pulse it triggers lasts 2-4 h, and IGF-1 accumulates with daily dosing. Absolute SC bioavailability is under 4%, which is why subcutaneous dosing is in the milligram rather than microgram range.

    Common Questions People Are Asking

    What is tesamorelin?

    Tesamorelin is a synthetic 44-amino-acid analogue of growth-hormone-releasing hormone (GHRH) stabilised with an N-terminal hexenoic acid. It signals the pituitary to release growth hormone and is the molecule approved (as Egrifta) to reduce excess visceral fat in HIV-associated lipodystrophy. New-U's tesamorelin is research-grade material supplied for laboratory use only — not the approved drug and not for human use.

    What does tesamorelin do?

    In the research and clinical literature tesamorelin activates the pituitary GHRH receptor to raise growth hormone and IGF-1, with a notable effect on visceral (deep abdominal) adipose tissue. These are findings for the molecule; New-U supplies research-grade tesamorelin for laboratory research only and implies no human therapeutic effect.

    What is tesamorelin used for?

    Clinically the approved drug is used to reduce visceral fat in HIV-associated lipodystrophy. In the research literature it is a tool compound for GH-axis and adipose-tissue studies. New-U supplies research-grade tesamorelin strictly for in-vitro and animal-model research, not for human use.

    Is tesamorelin FDA approved?

    The pharmaceutical tesamorelin (Egrifta) is FDA-approved for HIV-associated lipodystrophy. That approval applies to the finished prescription drug — NOT to research-grade material. New-U's tesamorelin is an unapproved research powder supplied for laboratory research only and is not a substitute for the prescription product.

    Is tesamorelin safe?

    As the approved drug Egrifta, tesamorelin has a human safety dataset under medical supervision. That record does not extend to research-grade material, which is not a sterile approved medicine and carries no human safety assurances. New-U supplies it for laboratory research only and makes no human-use claims.

    How is tesamorelin different from sermorelin or CJC-1295?

    All three are GHRH analogs, but tesamorelin is a full 44-amino-acid version with an N-terminal hexenoic acid for DPP-IV resistance. Sermorelin is the shorter 29-residue truncation with a shorter half-life, and CJC-1295 uses either tetrasubstitution (no-DAC) or covalent albumin binding (DAC) for different duration profiles. Tesamorelin has the strongest clinical dataset.

    Tesamorelin vs ipamorelin — what is the difference?

    They act on opposite ends of the same axis: tesamorelin is a GHRH-receptor analogue acting upstream on the pituitary, while ipamorelin is a selective ghrelin-receptor (GHSR) agonist. Tesamorelin has the heavier clinical dataset and a specific visceral-fat signal, whereas ipamorelin is prized for clean GH release with minimal cortisol or prolactin effect. Because they engage different receptors, the two are studied together as a complementary GHRH + secretagogue pairing rather than as substitutes.

    Why does tesamorelin reduce visceral fat specifically?

    GH itself preferentially mobilises visceral adipose tissue because visceral fat is more sensitive to catecholamine and GH-driven lipolysis than subcutaneous fat. Tesamorelin generates a physiologic GH pulse that targets exactly this compartment, which is why VAT drops while SAT is largely preserved.

    Does tesamorelin raise blood sugar?

    Like any GH-driven protocol, tesamorelin can transiently raise fasting glucose and worsen insulin sensitivity because GH opposes insulin action. Clinical trials reported modest glycemic changes that are typically manageable but warrant monitoring in research protocols.

    How should tesamorelin be stored?

    Keep the lyophilised powder frozen at −20 °C. After reconstitution with bacteriostatic water, refrigerate at 1-6 °C, protect from light, and use within the peptide's typical stability window. Avoid shaking, which can denature the peptide.

    What happens if you stop taking peptides?

    Tesamorelin is a GHRH analogue studied for its effect on visceral fat via the body's own GH release. The published clinical literature on the reference drug reports that the visceral-fat reduction is not maintained after the peptide is discontinued — visceral adipose tissue tends to return toward baseline — because the effect depends on ongoing GH-axis stimulation rather than a permanent change. Those findings describe the approved medicine in human studies; tesamorelin here is an unapproved research-grade peptide for laboratory research only and is not for human use.

    Where can I buy Tesamorelin?

    Right here — Tesamorelin is supplied directly by New-U Research Compounds on this page. Every batch is independently third-party tested to >99% HPLC purity with a batch-linked Certificate of Analysis, supplied as lyophilised research-grade material, and shipped direct from source worldwide in discreet, tracked packaging. Strictly for laboratory research use only — not for human use.

    How much does Tesamorelin cost?

    Tesamorelin pricing is shown live on this page, per pack size — 10-vial research packs as standard, with single-vial sample options on selected compounds. Larger vial strengths lower the per-mg cost, every order includes the batch Certificate of Analysis, and shipping is free on orders over $300.

    Is Tesamorelin third-party tested?

    Yes. Every Tesamorelin batch is verified by independent laboratories (Janoshik Analytics and Freedom Diagnostics) for identity and purity, with a batch-linked Certificate of Analysis confirming >99% purity by HPLC. Every order ships with its COA, and current batch certificates are published on our COA page.

    How do I buy Tesamorelin?

    Add the Tesamorelin pack size you need to your cart and check out: enter your shipping details, then choose your payment method — cryptocurrency or card — on the next step. Every order ships with its batch Certificate of Analysis (COA). Tesamorelin is supplied strictly for laboratory research use only, not for human or veterinary use.

    What payment methods can I use to buy Tesamorelin?

    At checkout you can pay by cryptocurrency (BTC, ETH, SOL, LTC, USDC, USDT and more) or by card, each handled by a dedicated secure payment provider. You choose your method after confirming your order.

    How fast is shipping, and do you ship worldwide?

    Yes — we ship worldwide in discreet, unmarked, temperature-stable, tracked packaging. Delivery typically takes 6–14 business days, and shipping is free on orders over $300.

    Is it legal to buy Tesamorelin?

    In the United States, Tesamorelin is sold strictly for laboratory and research purposes only. It is not approved by the FDA for human consumption and is not sold for that purpose. Regulatory status varies by jurisdiction — buyers are responsible for compliance in their own region.

    Pharmacokinetics

    Half-life Elimination t½ ~8–26 min; the triggered GH pulse lasts 2–4 h Absorption route Subcutaneous injection; Tmax ~0.15 h (median) Bioavailability Absolute subcutaneous bioavailability <4% (the reason dosing is in the milligram, not microgram, range) Metabolism / clearance Proteolytic clearance; the N-terminal trans-3-hexenoyl group confers DPP-IV resistance Stability Lyophilised: −20 °C. Reconstituted: 1–6 °C, protect from light; avoid shaking Notes IGF-1 accumulates over weeks of daily dosing; AUC ~34% higher in HIV-infected than healthy subjects.

    Research-Observed Effects

  • ~15–18% visceral adipose-tissue reduction over 26 weeks with 2 mg daily, with subcutaneous fat largely preserved (Falutz 2007, NEJM)
  • Reduced liver fat and slowed fibrosis progression in HIV-associated NAFLD over 12 months (Stanley 2019, Lancet HIV)
  • IGF-1 elevated 1.5–3× baseline while preserving somatostatin-regulated GH pulsatility
  • Improvement in dyslipidaemia (triglycerides) reported alongside visceral-fat reduction
  • The only GHRH analogue with full FDA approval (2010; updated F8 formulation more recently)
  • Published Research Context

    In the registration trials the reference drug was administered as 2 mg once daily subcutaneously, with visceral-fat and IGF-1 effects measured over 26–52 weeks. New-U supplies research vials at 5 mg and 10 mg. These figures describe the published clinical-trial schedule for the approved drug and are recorded here as research context only.

    Stacking Compatibility

    Compatible compounds

  • Ipamorelin: GHRH-receptor (tesamorelin) + ghrelin-receptor (ipamorelin) co-activation produces supra-additive GH release
  • GHRP-2: Alternative ghrelin-receptor agonist partner for amplifying the GH pulse
  • Avoid combinations

  • CJC-1295 / Sermorelin (other GHRH analogues): Redundant GHRH-receptor occupancy — no additive research rationale
  • Exogenous recombinant GH: Direct GH dosing suppresses the endogenous axis the GHRH analogue is meant to stimulate
  • Side Effects (Observed in Literature)

    Common

  • Injection-site reactions (most common in trials)
  • Arthralgia and myalgia
  • Peripheral oedema / fluid retention
  • Paraesthesia (numbness or tingling)
  • Rare

  • Hypersensitivity reactions
  • Glucose intolerance / new-onset hyperglycaemia (GH opposes insulin action)
  • Dose-dependent

  • GH-driven glucose elevation and fluid retention scale with sustained IGF-1 elevation — monitored in trials
  • Evidence Tier

    Overall: Tier 1: Human clinical

    Tesamorelin has the strongest clinical dataset of the GHRH-analogue class and is FDA-approved as a finished pharmaceutical. The research-grade material supplied here is NOT the approved drug and is unapproved laboratory material.

    Tier 1 · Human clinical

  • Falutz et al. NEJM 2007 — phase 3 RCT, 412 participants, ~18% visceral-fat reduction at 26 weeks
  • Stanley et al. Lancet HIV 2019 — RCT of liver fat / fibrosis in HIV-associated NAFLD
  • FDA approval (2010) for HIV-associated lipodystrophy — the only approved GHRH analogue
  • Source References & Further Reading

    Last reviewed: 16 June 2026 · New-U Research Compounds

  • Falutz J et al. Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV. N Engl J Med. · 2007 · DOI: 10.1056/NEJMoa072375
  • Stanley TL et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. · 2019 · PMID: 31611038 · DOI: 10.1016/S2352-3018(19)30338-8
  • PubMed: peer-reviewed literature on Tesamorelin
  • ClinicalTrials.gov: registered studies on Tesamorelin
  • Tesamorelin: Wikipedia
  • WebMD: consumer health reference
  • BBC News: Health
  • CNN Health: “Peptides: what to know about the wellness trend”
  • Sky News: “Can peptides make America healthy again?”
  • Sky News: “Inside the exploding US peptides craze” (video)
  • Sky News Australia: “Black market peptide trade explodes as influencers fuel uptick in use”
  • Sky News Australia: “Backyard peptide boom sparks alarm” (video)
  • Sky News Australia: “Oprah reveals struggle with shame of weight-loss drugs”
  • Key Characteristics

  • 44-amino-acid synthetic GHRH analog
  • N-terminal trans-3-hexenoic acid blocks DPP-IV cleavage
  • FDA-approved for HIV lipodystrophy (2010)
  • Preserves natural somatostatin feedback control
  • Typical daily SC dose 1.4-2 mg
  • Elevates IGF-1 1.5-3× over baseline with daily use
  • Under study for MASLD and visceral fat research
  • Research-grade purity: >99% HPLC
  • Specifications

    Molecular Formula C 221 H 366 N 72 O 67 S Molecular Weight 5135.9 Da Sequence 44-aa GHRH analog with N-terminal hexenoic acid Purity >99% (HPLC) Form Lyophilised powder Half-life 8-26 min (elimination); pulse lasts 2-4 h Bioavailability (SC) <4% Route Subcutaneous injection, once daily Storage Lyophilised: −20 °C freezer. Reconstituted: 1-6 °C, away from light.

    About Tesamorelin (TH-9507): GHRH Analogue Research Guide for Visceral Fat, Liver Fat and IGF-1

    Tesamorelin (TH-9507) is a stabilised GHRH(1-44) analogue developed by Theratechnologies specifically to solve the problem of excess visceral fat in people with HIV-associated lipodystrophy - a tissue-distribution syndrome that standard weight-loss approaches could not address. The small N-terminal trans-3-hexenoic acid tag that makes tesamorelin DPP-IV resistant is the whole difference between a peptide that lasts minutes and one that can generate a measurable, physiologic growth-hormone pulse.

    The phase 3 results were striking. Falutz et al. (NEJM, 2007) reported roughly an 18% reduction in visceral adipose tissue over 26 weeks without significant changes in subcutaneous fat, and that selective visceral effect is why tesamorelin remains a reference compound for researchers studying metabolic dysfunction more broadly. Newer work in HIV-associated NAFLD (Stanley et al., Lancet HIV 2019) showed reduced liver fat and slowed fibrosis progression over 12 months, anchoring its current interest in MASLD/MASH research. Because it works upstream on the GHRH receptor, it is also studied alongside ghrelin-receptor secretagogues such as ipamorelin.

    New-U Research Compounds supplies tesamorelin as a sterile lyophilised powder at >99% HPLC purity, verified by independent third-party labs, in 5 mg or 10 mg vials. It is for in-vitro and preclinical laboratory research only, is not the approved drug (Egrifta), and is not a substitute for any prescribed pharmaceutical. Nothing on this page is medical advice.

  • Tesamorelin - Wikipedia
  • Growth hormone-releasing hormone - Wikipedia
  • Lipodystrophy - Wikipedia
  • Non-alcoholic fatty liver disease - Wikipedia
  • Customer Reviews

    No customer reviews yet — be the first to share your experience.

    More in HGH / Somatropin

  • Sermorelin
  • CJC-1295 (with DAC)
  • CJC-1295 (without DAC)
  • Ipamorelin
  • Hexarelin
  • GHRP-2
  • Tesamorelin vs related HGH / Somatropin compounds

    Compound Price Purity spec COA Tesamorelin from $47 >99% HPLC On request Sermorelin from $43 >99% HPLC On request CJC-1295 (with DAC) from $59 >99% HPLC 1 published batch
  • Tesamorelin vs Sermorelin — full comparison
  • Tesamorelin vs CJC-1295 (with DAC) — full comparison
  • Descriptive catalog comparison for research sourcing decisions — not dosing guidance. All compounds are for laboratory research use only.

    More on Tesamorelin

  • Tesamorelin research guide
  • Buy Tesamorelin — pricing & packs
  • Research use only — not for human consumption. All products are supplied strictly for laboratory research purposes.

    © 2026 New-U Research Compounds · new-u.io — Copyright held with Hilxera Distribution Services LLC. All rights reserved.